Literature DB >> 29650607

Sulfonylurea treatment in type 2 diabetes.

Kirstin Bester1, Joey Ton2, Christina Korownyk3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29650607      PMCID： PMC5897073     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  13 in total

1.  2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

Authors:  Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay Patel; Maximilian von Eynatten; Klaus A Dugi; Hans-Juergen Woerle
Journal:  Lancet       Date:  2012-06-28       Impact factor: 79.321

2.  Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Authors:  Olga Vaccaro; Maria Masulli; Antonio Nicolucci; Enzo Bonora; Stefano Del Prato; Aldo P Maggioni; Angela A Rivellese; Sebastiano Squatrito; Carlo B Giorda; Giorgio Sesti; Paolo Mocarelli; Giuseppe Lucisano; Michele Sacco; Stefano Signorini; Fabrizio Cappellini; Gabriele Perriello; Anna Carla Babini; Annunziata Lapolla; Giovanna Gregori; Carla Giordano; Laura Corsi; Raffaella Buzzetti; Gennaro Clemente; Graziano Di Cianni; Rossella Iannarelli; Renzo Cordera; Olga La Macchia; Chiara Zamboni; Cristiana Scaranna; Massimo Boemi; Ciro Iovine; Davide Lauro; Sergio Leotta; Elisabetta Dall'Aglio; Emanuela Cannarsa; Laura Tonutti; Giuseppe Pugliese; Antonio C Bossi; Roberto Anichini; Francesco Dotta; Antonino Di Benedetto; Giuseppe Citro; Daniela Antenucci; Lucia Ricci; Francesco Giorgino; Costanza Santini; Agostino Gnasso; Salvatore De Cosmo; Donatella Zavaroni; Monica Vedovato; Agostino Consoli; Maria Calabrese; Paolo di Bartolo; Paolo Fornengo; Gabriele Riccardi
Journal:  Lancet Diabetes Endocrinol       Date:  2017-09-13       Impact factor: 32.069

3.  The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.

Authors:  Jun Sung Moon; Kyoung Soo Ha; Ji Sung Yoon; Hyoung Woo Lee; Hyun Chul Lee; Kyu Chang Won
Journal:  Acta Diabetol       Date:  2014-01-21       Impact factor: 4.280

4.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

Authors:  C L Meinert; G L Knatterud; T E Prout; C R Klimt
Journal:  Diabetes       Date:  1970       Impact factor: 9.461

5.  Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  Victor Lawrence Roberts; John Stewart; Maher Issa; Barbara Lake; Robert Melis
Journal:  Clin Ther       Date:  2005-10       Impact factor: 3.393

6.  Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study.

Authors:  Graziella Bruno; Annibale Biggeri; Franco Merletti; Giuseppe Bargero; Stefania Ferrero; Gianfranco Pagano; Paolo Cavallo Perin
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.

Authors:  R F Coniff; J A Shapiro; T B Seaton; G A Bray
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

Review 9.  Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.

Authors:  O J Phung; E Schwartzman; R W Allen; S S Engel; S N Rajpathak
Journal:  Diabet Med       Date:  2013-10       Impact factor: 4.359

10.  Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

Authors:  Jie Hong; Yifei Zhang; Shenghan Lai; Ankang Lv; Qing Su; Yan Dong; Zhiguang Zhou; Weili Tang; Jiajun Zhao; Lianqun Cui; Dajin Zou; Dawang Wang; Hong Li; Chao Liu; Guoting Wu; Jie Shen; Dalong Zhu; Weiqing Wang; Weifeng Shen; Guang Ning
Journal:  Diabetes Care       Date:  2012-12-10       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.